Journal
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Volume 28, Issue 2, Pages 130-135Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2017.0085
Keywords
atomoxetine; parent training; ADHD; sleep disturbance; autism spectrum disorder; clinical trial
Categories
Funding
- National Institute of Mental Health [1R01MH079080-01A2, 5R01MH079082-05, R01 MH083247]
- University of Rochester CTSA [UL1 RR024160]
- Ohio State University CTSA from the National Center for Research Resources [UL1TR001070]
- National Center for Advancing Translational Sciences of the National Institutes of Health
- Eli Lilly and Company
Ask authors/readers for more resources
Objective: Sleep disturbance is often a problem for children with either autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD). Psychostimulant medications used to treat ADHD symptoms can exacerbate this problem. For children with ASD and ADHD, atomoxetine (ATX) is a viable alternative to psychostimulants. We investigated the effects of ATX and a manualized parent training (PT) program targeting noncompliance, on the sleep quality of children with ASD and ADHD. Methods: Participants in a randomized clinical trial were treated with ATX + PT, ATX alone, PT alone, or placebo (PBO) alone, for 10 weeks. Fifty-four of 128 (42%) caregivers completed the Children's Sleep Habits Questionnaire (CSHQ) at baseline and endpoint. Analysis of covariance was used to investigate possible differences between treatment groups. Results: There were no significant differences between treatment groups, including PBO on the CSHQ 33-Item total score, total hours of sleep per day, and total minutes awake after sleep onset at the study endpoint. Conclusion: ATX appears sleep neutral. Clinicians who treat ADHD symptoms in children and adolescents with ASD may prefer ATX over psychostimulants when sleep disturbance is an issue.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available